Pretreatment with high-dose statin, but not low-dose statin, ezetimibe, or the combination of low-dose statin and ezetimibe, limits infarct size in the rat

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 13, Issue 1, 2008, Pages 72-79

  Birnbaum, Yochai ^a   Lin, Yu ^a   Ye, Yumei ^a   Merla, Ramanna ^a   Perez Polo, Jose R ^a   Uretsky, Barry F ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Ezetimibe; Infarct size; Nitric oxide synthase; Prostacyclin; Statins

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; ATORVASTATIN; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRIC OXIDE SYNTHASE; PROSTACYCLIN; SIMVASTATIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MEGADOSE; ENZYME ACTIVITY; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE REPERFUSION; HEART PROTECTION; LOW DRUG DOSE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

6-KETOPROSTAGLANDIN F1 ALPHA; ANIMALS; ANTICHOLESTEREMIC AGENTS; AZETIDINES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; NITRIC OXIDE SYNTHASE; PYRROLES; RATS; RATS, SPRAGUE-DAWLEY; SIMVASTATIN; UP-REGULATION;

EID: 39049103901     PISSN: 10742484     EISSN: None     Source Type: Journal    
DOI: 10.1177/1074248407312839     Document Type: Article

References (55)

1. Arnaud C., Mach F. Pleiotropic effects of statins in atherosclerosis: role on endothelial function, inflammation and immunomodulation. Arch Mal Coeur Vaiss. 2005 ; 98: 661-666.
2. Calabro P., Yeh ET The pleiotropic effects of statins. Curr Opin Cardiol. 2005 ; 20: 541-546.
3. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005 ; 352: 1425-1435.
4. Nissen SE Effect of intensive lipid lowering on progression of coronary atherosclerosis: evidence for an early benefit from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial. Am J Cardiol. 2005 ; 96: 61F - 68F.
5. Cannon CP, Braunwald E., McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004 ; 350: 1495-1504.
6. Zhou Z., Rahme E., Pilote L. Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention. Am Heart J. 2006 ; 151: 273-281.
7. Lipka LJ Ezetimibe: a first-in-class, novel cholesterol absorption inhibitor. Cardiovasc Drug Rev. 2003 ; 21: 293-312.
8. Sager PT, Capece R., Lipka L., et al. Effects of ezetimibe coadministered with simvastatin on C-reactive protein in a large cohort of hypercholesterolemic patients. Atherosclerosis. 2005 ; 179: 361-367.
9. Bays HE, Ose L., Fraser N., et al. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia. Clin Ther. 2004 ; 26: 1758-1773.
10. Sager PT, Melani L., Lipka L., et al. Effect of coadministration of ezetimibe and simvastatin on high-sensitivity C-reactive protein. Am J Cardiol. 2003 ; 92: 1414-1418.
11. Ballantyne CM, Houri J., Notarbartolo A., et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation. 2003 ; 107: 2409-2415.
12. Dotani MI, Elnicki DM, Jain AC, Gibson CM Effect of preoperative statin therapy and cardiac outcomes after coronary artery bypass grafting. Am J Cardiol. 2000 ; 86: 1128-1130.
13. Lindenauer PK, Pekow P., Wang K., Gutierrez B., Benjamin EM Lipid-lowering therapy and in-hospital mortality following major noncardiac surgery. JAMA. 2004 ; 291: 2092-2099.
14. Herrmann J., Lerman A., Baumgart D., et al. Preprocedural statin medication reduces the extent of periprocedural non-Q-wave myocardial infarction. Circulation. 2002 ; 106: 2180-2183.
15. Chan AW, Bhatt DL, Chew DP, et al. Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention Circulation. 2002 ; 105: 691-696.
16. Poldermans D., Bax JJ, Kertai MD, et al. Statins are associated with a reduced incidence of perioperative mortality in patients undergoing major noncardiac vascular surgery. Circulation. 2003 ; 107: 1848-1851.
17. Durazzo AE, Machado FS, Ikeoka DT, et al. Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial [discussion]. J Vasc Surg. 2004 ; 39: 967-976.
18. Pasceri V., Patti G., Nusca A., Pristipino C., Richichi G., Di Sciascio G. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation. 2004 ; 110: 674-678.
19. Fleisher LA, Beckman JA, Brown KA, et al. ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery) developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery J Am Coll Cardiol. 2007 ; 50: e159 - e241.
20. Birnbaum Y., Ashitkov T., Uretsky BF, Ballinger S., Motamedi M. Reduction of infarct size by short-term pretreatment with atorvastatin. Cardiovasc Drugs Ther. 2003 ; 17: 25-30.
21. Birnbaum Y., Ye Y., Rosanio S., et al. Prostaglandins mediate the cardioprotective effects of atorvastatin against ischemia-reperfusion injury. Cardiovasc Res. 2005 ; 65: 345-355.
22. Atar S., Ye Y., Lin Y., et al. Atorvastatin-induced cardioprotection is mediated by increasing inducible nitric oxide synthase and consequent S-nitrosylation of cyclooxygenase-2. Am J Physiol Heart Circ Physiol. 2006 ; 290: H1960 - H1968.
23. Tavackoli S., Ashitkov T., Hu ZY, Motamedi M., Uretsky BF, Birnbaum Y. Simvastatin-induced myocardial protection against ischemia-reperfusion injury is mediated by activation of ATP-sensitive K+ channels. Coron Artery Dis. 2004 ; 15: 53-58.
24. Wolfrum S., Grimm M., Heidbreder M., et al. Acute reduction of myocardial infarct size by a hydroxymethyl glutaryl coenzyme A reductase inhibitor is mediated by endothelial nitric oxide synthase. J Cardiovasc Pharmacol. 2003 ; 41: 474-480.
25. Scalia R., Gooszen ME, Jones SP, et al. Simvastatin exerts both anti-inflammatory and cardioprotective effects in apolipoprotein E-deficient mice. Circulation. 2001 ; 103: 2598-2603.
26. Jones SP, Trocha SD, Lefer DJ Pretreatment with simvastatin attenuates myocardial dysfunction after ischemia and chronic reperfusion. Arterioscler Thromb Vasc Biol. 2001 ; 21: 2059-2064.
27. Sanada S., Asanuma H., Minamino T., et al. Optimal windows of statin use for immediate infarct limitation: 5'nucleotidase as another downstream molecule of phosphatidylinositol 3-kinase. Circulation. 2004 ; 110: 2143-2149.
28. Bulhak AA, Gourine AV, Gonon AT, Sjoquist PO, Valen G., Pernow J. Oral pre-treatment with rosuvastatin protects porcine myocardium from ischaemia/reperfusion injury via a mechanism related to nitric oxide but not to serum cholesterol level. Acta Physiol Scand. 2005 ; 183: 151-159.
29. Lazar HL, Bao Y., Zhang Y., Bernard SA Pretreatment with statins enhances myocardial protection during coronary revascularization. J Thorac Cardiovasc Surg. 2003 ; 125: 1037-1042.
30. Manickavasagam S., Ye Y., Lin Y., et al. The cardioprotective effect of a statin and cilostazol combination: relationship to akt and endothelial nitric oxide synthase activation. Cardiovasc Drugs Ther. 2007 ; 21: 321-330.
31. Ye Y., Lin Y., Perez-Polo R., et al. Enhanced cardioprotection against ischemia-reperfusion injury with a dipyridamole and low-dose atorvastatin combination. Am J Physiol Heart Circ Physiol. 2007 ; 293: H813 - H818.
32. United States National Institutes of Health. The Guide for the Care and Use of Laboratory Animals Bethedsa, MD: National Institutes of Health ; 1996. NIH Publication 85-23.
33. Rosanio S., Ye Y., Atar S., et al. Enhanced cardioprotection against ischemia-reperfusion injury with combining sildenafil with low-dose atorvastatin. Cardiovasc Drugs Ther. 2006 ; 20: 27-36.
34. Ye Y., Lin Y., Atar S., et al. Myocardial protection by pioglitazone, atorvastatin, and their combination: mechanisms and possible interactions. Am J Physiol Heart Circ Physiol. 2006 ; 291: H1158 - H1169.
35. Amin-Hanjani S., Stagliano NE, Yamada M., Huang PL, Liao JK, Moskowitz MA Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice. Stroke. 2001 ; 32: 980-986.
36. Endres M., Laufs U., Huang Z., et al. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci U S A. 1998 ; 95: 8880-8885.
37. Jones S., Gibson M., Rimmer D., Gibson T., Sharp B., Lefer D. Direct vascular and cardioprotective effects of rosuvastatin, a new HMG-CoA reductase inhibitor. J Am Coll Cardiol. 2002 ; 40: 1172-1178.
38. Bell RM, Yellon DM Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway. J Am Coll Cardiol. 2003 ; 41: 508-515.
39. Laufs U., Gertz K., Huang P., et al. Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice. Stroke. 2000 ; 31: 2442-2449.
40. Hernandez-Perera O., Perez-Sala D., Navarro-Antolin J., et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest. 1998 ; 101: 2711-2719.
41. Laufs U., La Fata V., Plutzky J., Liao JK Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 1998 ; 97: 1129-1135.
42. Laufs U., Gertz K., Dirnagl U., Bohm M., Nickenig G., Endres M. Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice. Brain Res. 2002 ; 942: 23-30.
43. Thakur NK, Hayashi T., Sumi D., Kano H., Tsunekawa T., Iguchi A. HMG-CoA reductase inhibitor stabilizes rabbit atheroma by increasing basal NO and decreasing superoxide. Am J Physiol Heart Circ Physiol. 2001 ; 281: H75 - H83.
44. Mital S., Zhang X., Zhao G., et al. Simvastatin upregulates coronary vascular endothelial nitric oxide production in conscious dogs. Am J Physiol Heart Circ Physiol. 2000 ; 279: H2649 - H2657.
45. Kureishi Y., Luo Z., Shiojima I., et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med. 2000 ; 6: 1004-1010.
46. Brouet A., Sonveaux P., Dessy C., Moniotte S., Balligand JL, Feron O. Hsp90 and caveolin are key targets for the proangiogenic nitric oxide-mediated effects of statins. Circ Res. 2001 ; 89: 866-873.
47. Wolfrum S., Dendorfer A., Schutt M., et al. Simvastatin acutely reduces myocardial reperfusion injury in vivo by activating the phosphatidylinositide 3-kinase/Akt pathway. J Cardiovasc Pharmacol. 2004 ; 44: 348-355.
48. Efthymiou CA, Mocanu MM, Yellon DM Atorvastatin and myocardial reperfusion injury: new pleiotropic effect implicating multiple prosurvival signaling. J Cardiovasc Pharmacol. 2005 ; 45: 247-252.
49. Lefer DJ, Scalia R., Jones SP, et al. HMG-CoA reductase inhibition protects the diabetic myocardium from ischemia-reperfusion injury Faseb J. 2001 ; 15: 1454-1456.
50. Wayman NS, Ellis BL, Thiemermann C. Simvastatin reduces infarct size in a model of acute myocardial ischemia and reperfusion in the rat. Med Sci Monit. 2003 ; 9: BR155 - BR159.
51. Skaletz-Rorowski A., Lutchman M., Kureishi Y., Lefer DJ, Faust JR, Walsh K. HMG-CoA reductase inhibitors promote cholesterol-dependent Akt/PKB translocation to membrane domains in endothelial cells. Cardiovasc Res. 2003 ; 57: 253-264.
52. Feron O., Dessy C., Desager JP, Balligand JL. Hydroxy-methylglutaryl- coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation. 2001 ; 103: 113-118.
53. Laufs U., Endres M., Stagliano N., et al. Neuroprotection mediated by changes in the endothelial actin cytoskeleton. J Clin Invest. 2000 ; 106: 15-24.
54. Birnbaum Y., Ye Y., Lin Y., et al. Augmentation of myocardial production of 15-epi-lipoxin-a4 by pioglitazone and atorvastatin in the rat. Circulation. 2006 ; 114: 929-935.
55. Ballantyne CM, Abate N., Yuan Z., King TR, Palmisano J. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study. Am Heart J. 2005 ; 149: 464-473.